HC Wainwright Predicts Weaker Earnings for Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Niagen Bioscience in a research note issued on Wednesday, August 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.21 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.05 EPS.

A number of other equities analysts have also recently issued reports on NAGE. Freedom Capital upgraded Niagen Bioscience to a “strong-buy” rating in a report on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday. Canaccord Genuity Group cut their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.33.

Niagen Bioscience Stock Down 14.7%

NASDAQ NAGE opened at $2.96 on Thursday. The stock’s 50-day simple moving average is $3.41 and its two-hundred day simple moving average is $4.34. Niagen Bioscience has a twelve month low of $2.87 and a twelve month high of $11.29. The company has a market capitalization of $235.73 million, a price-to-earnings ratio of 16.45 and a beta of 2.09.

Niagen Bioscience (NASDAQ:NAGE) last announced its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 18.31%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. New York State Teachers Retirement System bought a new stake in shares of Niagen Bioscience in the 4th quarter valued at about $30,000. Ameritas Investment Partners Inc. purchased a new position in Niagen Bioscience in the 3rd quarter worth approximately $45,000. Quantbot Technologies LP purchased a new position in Niagen Bioscience in the 3rd quarter worth approximately $48,000. Polymer Capital Management US LLC bought a new stake in Niagen Bioscience in the third quarter valued at approximately $96,000. Finally, BNP Paribas Financial Markets bought a new stake in Niagen Bioscience in the third quarter valued at approximately $96,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.